General InformationStipple Bio is a synthetic biology company founded in 2019 and headquartered in California with 11-50 employees, focused on cell programming technology for therapeutic applications.
Funding & FinancialsThe company has raised Series A funding to advance its synthetic biology platform, though specific total funding amounts and lead investors are not publicly detailed in available sources.
Leadership & TeamThe company was founded by bioengineering and synthetic biology experts, with leadership focused on cell programming and immunotherapy development, though specific current executive names require direct company verification.
Recent ActivityStipple Bio has been advancing its cell programming platform for cancer immunotherapy applications and expanding its pipeline of programmable cell therapeutics in the regenerative medicine and oncology spaces.